Revolution Medicines (NASDAQ: RVMD) saw its shares climb 2.3% in premarket trading on Thursday, following the official U.S. launch of its first commercial product, RASONQUE. The stock had already gained 1.9% in Wednesday's regular session, closing at $215.44, and was last seen at $220.46 before the market open.
The debut of RASONQUE, a once-daily oral therapy for pancreatic cancer, marks a significant milestone for the biotech firm. Priced at a wholesale acquisition cost of $39,800 for a 30-day supply, the drug is now available for adults with metastatic pancreatic adenocarcinoma who have previously received other treatments, as well as those who cannot undergo multiagent chemotherapy.
RBC Capital Markets has maintained its Outperform rating on the stock, projecting U.S. sales of $28 million for the third quarter and a sharp acceleration to $148 million in the fourth quarter. The firm's 2027 forecast stands at $1.1 billion. These projections translate to roughly 3,719 wholesale units per month in Q4, or about 1,240 units monthly after accounting for typical discounts and patient assistance programs. Notably, over 2,000 patients had already gained early access to the drug prior to the official launch.
The market's enthusiasm is underpinned by robust clinical data from the RASolute 302 trial. The study, which enrolled 500 adults, demonstrated a median overall survival of 13.2 months for RASONQUE compared to 6.7 months for standard chemotherapy, representing a 60% reduction in the risk of death (hazard ratio 0.40). Progression-free survival also doubled to 7.2 months, and the objective response rate was 30% versus 11% for chemotherapy.
One key differentiator is that the FDA label does not mandate a companion diagnostic, eliminating a testing step and broadening eligibility to patients with both known and unknown RAS mutations. Pancreatic adenocarcinoma affects approximately 55,000 Americans each year, providing a substantial addressable patient population.
Investors have already priced in considerable success. RVMD's market capitalization of $46.2 billion is roughly 42 times RBC's 2027 sales estimate for RASONQUE, though that multiple drops to about four when compared to the company's long-term worldwide revenue potential of $11.5 billion. The stock had previously surged over 40% in a single day following promising trial data in April, reflecting high expectations for regulatory approval.
The company's balance sheet appears well-positioned to support the commercial rollout. As of June 30, Revolution Medicines reported $3.9 billion in cash and investments. Research and development expenses for the second quarter totaled $394.9 million, while general and administrative costs climbed to $110.2 million, reflecting the build-out of commercial infrastructure.
Analyst sentiment remains overwhelmingly positive, with 19 analysts covering the stock and a consensus Buy rating. Among them, 42% rate it a Strong Buy, while only 5% suggest a Hold. However, the rollout carries inherent risks, including insurance coverage hurdles, manufacturing capacity constraints, patient adoption rates, and tolerability issues. The label warns of skin toxicity, diarrhea, gastrointestinal perforation, and lung inflammation.
Looking ahead, investors will be closely monitoring prescription trends and net pricing data. The first official sales report will be a critical test of whether clinical demand translates into reimbursed usage, which could prove more impactful than Thursday's modest premarket uptick. As the company navigates its commercial debut, the focus shifts from regulatory milestones to real-world market execution.
